US Bancorp
RYTM icon

US Bancorp’s Rhythm Pharmaceuticals RYTM Stock Holding History

US Bancorp’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$113K Sell
1,020
-21
-2% -$1.9K ﹤0.01% 2385
2026
Q1 		$90.5K Buy
1,041
+88
+9% +$8.56K ﹤0.01% 2436
2025
Q4 		$102K Buy
953
+807
+553% +$85.6K ﹤0.01% 2356
2025
Q3 		$14.7K Hold
146
– – ﹤0.01% 3189
2025
Q2 		$9.23K Hold
146
– – ﹤0.01% 3458
2025
Q1 		$7.73K Buy
146
+5
+4% +$277 ﹤0.01% 3521
2024
Q4 		$7.89K Hold
141
– – ﹤0.01% 3504
2024
Q3 		$7.39K Hold
141
– – ﹤0.01% 3459
2024
Q2 		$5.79K Buy
141
+79
+127% +$3.15K ﹤0.01% 3471
2024
Q1 		$2.69K Hold
62
– – ﹤0.01% 3666
2023
Q4 		$2.85K Sell
62
-48
-44% -$1.51K ﹤0.01% 3647
2023
Q3 		$2.52K Sell
110
-953
-90% -$21.3K ﹤0.01% 3602
2023
Q2 		$17.5K Buy
1,063
+1,018
+2,262% +$18.4K ﹤0.01% 3039
2023
Q1 		$803 Hold
45
– – ﹤0.01% 3901
2022
Q4 		$1.31K Hold
45
– – ﹤0.01% 3879
2022
Q3 		$1K Buy
+45
New +$837 ﹤0.01% 4001
2022
Q2 		– Sell
-130
Closed -$1K – 4205
2022
Q1 		$1K Sell
130
-3,034
-96% -$26.6K ﹤0.01% 3989
2021
Q4 		$32K Buy
3,164
+3,068
+3,196% +$34.5K ﹤0.01% 2875
2021
Q3 		$1K Sell
96
-40
-29% -$611 ﹤0.01% 4011
2021
Q2 		$3K Sell
136
-358
-72% -$7.43K ﹤0.01% 3759
2021
Q1 		$11K Sell
494
-335
-40% -$9.72K ﹤0.01% 3251
2020
Q4 		$25K Buy
829
+368
+80% +$9.35K ﹤0.01% 2823
2020
Q3 		$10K Buy
461
+356
+339% +$8.16K ﹤0.01% 3086
2020
Q2 		$2K Buy
+105
New +$2.05K ﹤0.01% 3529
2019
Q2 		– Sell
-99
Closed -$3K – 3661
2019
Q1 		$3K Buy
+99
New +$2.85K ﹤0.01% 3362

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

US Bancorp's RYTM Position: Q2 2026 in Review

US Bancorp reduced its Rhythm Pharmaceuticals (RYTM) stake by 2% in Q2 2026, selling an estimated $1.9K and leaving 1,020 shares worth $113K. The position accounts for ﹤0.01% of the portfolio, ranked #2385.

US Bancorp first reported a position in RYTM in Q1 2019 and has held it in 25 quarters since. 304 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • US Bancorp held 1,020 shares of Rhythm Pharmaceuticals worth $113K as of Q2 2026.
  • US Bancorp sold 21 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $1.9K.
  • Rhythm Pharmaceuticals made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #2385 holding.
  • US Bancorp first reported a position in Rhythm Pharmaceuticals in Q1 2019 and has held it in 25 quarters since.
  • 304 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.